EVE.SW stock -6.02% intraday at CHF0.78 on 13 Jan 2026: Watch cash per share
EVE.SW stock fell -6.02% intraday to CHF0.78 on 13 Jan 2026, making it one of the top losers on the SIX Switzerland healthcare list today. Trading volume is 14,166 shares, nearly 2.54x average volume, signalling short-term selling pressure. The move follows weak near-term momentum versus the 50-day average CHF0.84 and the 200-day average CHF1.02. We use Meyka AI as an AI-powered market analysis platform to frame liquidity, valuation and a short-term price outlook for EvoNext Holdings S.A. (EVE.SW) on the SIX.
EVE.SW stock: Intraday move and quick facts
Today EVE.SW on the SIX is at CHF0.78, down -0.05 CHF or -6.02%, with a day range CHF0.77–0.80. Market cap is CHF5,625,011 and shares outstanding are 7,211,552. Key micro facts: EPS -0.12, PE -6.50, year high CHF1.69 and year low CHF0.75. The intraday volume 14,166 exceeds the average 5,568, which highlights active selling in this session.
Financials and valuation: EVE.SW stock fundamentals
EvoNext reports a strong liquidity profile with cash per share CHF0.87 and a current ratio 8.34, but negative profitability: net income per share -0.12 and ROE -13.27%. Price-to-book is 0.90, below the healthcare sector average PB 4.51, indicating a deep discount to peers. Operating and free cash flow per share are -0.14 CHF. These figures show solvent balance-sheet metrics but persistent operating losses.
Technicals and trading setup for EVE.SW stock
Technicals show mixed signals. RSI is 52.91 and ADX 29.43, pointing to a developing trend. Bollinger middle band sits at CHF0.80; ATR is 0.05 CHF, and the stock trades below its 50-day average CHF0.84 and 200-day CHF1.02. On intraday weakness, immediate support is the year low CHF0.75 and resistance near CHF0.85. Overbought MFI reading earlier suggests recent buying faded into selling pressure.
Meyka AI rates EVE.SW with a score out of 100
Meyka AI rates EVE.SW with a score out of 100: 64.23 (B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company-side metrics push the grade lower (negative ROE, negative EPS) while strong cash per share and low PB support a neutral view. These grades are informational only and are not financial advice.
Risks and sector context affecting EVE.SW stock
EvoNext operates in Biotechnology within Healthcare where the average PE is 33.47 and avg PB 4.51. EVE.SW’s negative earnings and small market cap CHF5.63M raise liquidity and scale risk. Key risks: continued operating losses, low trading depth, and biotech regulatory hurdles for ingredient commercialisation. Sector strength can help but the stock needs sustained revenue growth to close the valuation gap.
EVE.SW stock: Price forecasts and analyst-style targets
Meyka AI’s forecast model projects a short-term monthly target CHF0.82, a quarterly target CHF1.17, and a 12-month model target CHF3.13. From the current CHF0.78, those imply upside of 5.13%, 50.00%, and 301.61% respectively. Use these as scenario levels, not guarantees. For traders, watch the 50-day CHF0.84 and 200-day CHF1.02 as tactical barriers; for investors, the priority is consistent revenue growth and margin improvement.
Final Thoughts
EVE.SW stock is trading as a top intraday loser on 13 Jan 2026 after a -6.02% drop to CHF0.78 on elevated volume. The company shows a solid cash buffer with CHF0.87 cash per share and a high current ratio 8.34, but profitability remains negative with EPS -0.12 and ROE -13.27%. Meyka AI’s forecast model projects CHF0.82 (monthly), CHF1.17 (quarterly) and CHF3.13 (12 months). Versus today’s price, those imply potential upside of 5.13%, 50.00%, and 301.61% respectively. Short-term traders should treat the stock as high volatility given thin market cap CHF5.63M and a rel. volume of 2.54x; longer-term investors must see revenue and margin improvement before re-rating to sector multiples. Forecasts are model-based projections and not guarantees. For company filings and details visit EvoNext Holdings S.A. and our EVE.SW page on Meyka for live updates and additional metrics: EVE.SW on Meyka.
FAQs
Why did EVE.SW stock fall intraday today?
EVE.SW stock fell -6.02% intraday to CHF0.78 on 13 Jan 2026 amid heavier volume (14,166) and selling pressure. Technical weakness below the 50-day average and lack of near-term earnings or positive catalysts amplified the drop.
What are the main financial strengths for EVE.SW stock?
EvoNext has strong liquidity: cash per share CHF0.87 and current ratio 8.34. Price-to-book 0.90 signals low market valuation versus book. These balance-sheet strengths reduce short-term solvency risk.
What price targets does Meyka provide for EVE.SW stock?
Meyka AI’s forecast model projects CHF0.82 (monthly), CHF1.17 (quarterly) and CHF3.13 (12 months). These imply upside of 5.13%, 50.00%, and 301.61% from CHF0.78. Forecasts are model-based projections and not guarantees.
Is EVE.SW stock a buy for long-term investors?
EVE.SW stock may merit a HOLD for investors focused on balance-sheet strength but not yet a clear BUY. Meyka grades the stock B (HOLD) due to cash reserves but negative profitability and small market cap that limit conviction.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
